Description
• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
-
Moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate.
-
Active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
-
Moderate to severe ulcerative colitis in adults who have had an inadequate response or intolerance to conventional therapy or a TNF blocker.
-
Active ankylosing spondylitis in adults who have had an inadequate response or intolerance to conventional therapy.
Pharmacology:
Tofacitinib is an oral Janus kinase (JAK) inhibitor that works by interfering with the JAK-STAT signaling pathway, which is involved in the process of inflammation and immune cell function. By inhibiting JAK enzymes, tofacitinib reduces the activity of the immune system and inflammation associated with various autoimmune diseases.
Dosage & Administration:
-
Rheumatoid Arthritis: 5 mg orally twice daily.
-
Psoriatic Arthritis: 5 mg orally twice daily.
-
Ulcerative Colitis: Induction dose of 10 mg orally twice daily for at least 8 weeks, then maintenance dose of 5 mg orally twice daily.
-
Ankylosing Spondylitis: 5 mg orally twice daily.
-
Administration: Swallow the tablet whole with or without food. Do not chew, crush, or break the tablet.
Interaction:
-
Strong CYP3A4 inhibitors: Concurrent use may increase the risk of tofacitinib side effects.
-
Live vaccines: Avoid use during treatment with tofacitinib.
-
Immunosuppressive agents: Use with caution when combined with other immunosuppressive drugs.
Contraindications:
-
Hypersensitivity to tofacitinib or any component of the tablet.
-
Active infections, including tuberculosis.
-
Severe hepatic impairment.
-
Absolute lymphocyte count less than 500 cells/mm³, absolute neutrophil count less than 1000 cells/mm³, or hemoglobin less than 9 g/dL.
Side Effects:
-
Common: Upper respiratory tract infections, headache, diarrhea, nasopharyngitis.
-
Serious: Risk of serious infections, lymphoma, other cancers, major cardiovascular events, blood clots.
-
Others: Elevated liver enzymes, increased cholesterol levels, anemia.
Pregnancy & Lactation:
-
Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus.
-
Lactation: It is not known whether tofacitinib is excreted in human milk. Caution should be exercised when administered to a nursing woman.
Precautions & Warnings:
-
Monitor for signs and symptoms of infection during treatment.
-
Regular blood tests are recommended to monitor blood counts, liver enzymes, and cholesterol levels.
-
Use with caution in patients with a history of cardiovascular disease or cancer.
-
Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants.
Therapeutic Class:
Disease-modifying antirheumatic drug (DMARD), Janus kinase (JAK) inhibitor.
Storage Conditions:
Store at room temperature, 20°C to 25°C (68°F to 77°F). Keep the container tightly closed and protect from moisture. Keep out of reach of children.
 100ML.jpg)
.jpg)
.jpg)
 10P.jpg)
.jpeg)
Change Language